Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9C6LN)

Drug Name

R-1479 Drug Info

Synonyms

4-Azidocytidine

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Discontinued in Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Mycobacterium RNA polymerase (MycB RNAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rifamycin	DMEH3O7	Diarrhea	ME05.1	Approved	[3]
Favipiravir	DMBZ27L	Influenza virus infection	1E30-1E32	Registered	[4]
TAS-106	DML97KB	Head and neck cancer	2D42	Phase 2	[5]
JTK-003	DMB0V5Y	Hepatitis C virus infection	1E51.1	Discontinued in Phase 2	[6]
XTL-2125	DM3Y6M7	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mycobacterium RNA polymerase (MycB RNAP)	TT79JGK	RPOA_MYCTU; RPOB_MYCTU; RPOC_MYCTU; RPOZ_MYCTU	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018944)
2	The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cel... J Biol Chem. 2006 Feb 17;281(7):3793-9.
3	Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4832-E4840.
4	Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54.
5	Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.Invest New Drugs.2012 Feb;30(1):316-26.
6	Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. Viruses. 2010 April; 2(4): 826-866.
7	DOI: 10.1111/j.1365-2036.2009.03927.x